Adaptimmune Therapeutics plc (MUN:473A)

Market Cap	509.70K -99.6%
Revenue (ttm)	55.42M -54.0%
Net Income	-144.55M
EPS	-0.56
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,650
Average Volume	83
Open	0.0190
Previous Close	0.0210
Day's Range	0.0175 - 0.0190
52-Week Range	0.0175 - 0.0340
Beta	n/a
RSI	n/a
Earnings Date	Mar 19, 2026

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company al...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 506
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: 473A

Financial Performance

In 2024, Adaptimmune Therapeutics's revenue was $178.03 million, an increase of 195.34% compared to the previous year's $60.28 million. Losses were -$70.81 million, -37.81% less than in 2023.

Financial numbers in USD